8-K: Vaxart Adjourns Annual Stockholders Meeting Amidst Push for Reverse Stock Split Approval

Vaxart, Inc. has adjourned its 2025 annual meeting of stockholders to June 13, 2025, to allow additional time for shareholders to vote on a critical proposal to enable a reverse stock split, deemed necessary for continued Nasdaq listing.

Summary

• Vaxart, Inc. reconvened its 2025 annual meeting of stockholders on June 2, 2025, with approximately 67.89% of outstanding shares represented, constituting a quorum.
• The meeting was adjourned because there were insufficient votes to approve Proposal No. 2, which seeks to amend the company's Restated Certificate of Incorporation to allow the Board of Directors to effect a reverse stock split.
• The Board of Directors believes Proposal No. 2 is advisable and in the best interests of stockholders, particularly to ensure continued Nasdaq listing.
• The reconvened Annual Meeting will be held virtually on Friday, June 13, 2025, at 8:30 a.m. Pacific Time.
• Vaxart will continue to solicit votes, encouraging stockholders who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025.
• Proxies previously submitted will be voted at the adjourned meeting unless properly revoked, and stockholders who have already voted do not need to recast their votes.
• The record date for voting remains March 26, 2025.
• Leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis, recommend supporting Proposal No. 2.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the failure to pass a critical proposal at the initial meeting, which indicates a challenge in shareholder alignment. However, the company is actively addressing the issue, has support from proxy advisory firms, and management reports positive engagement with large shareholders, mitigating a more severe negative outlook.

Positives

• A quorum was achieved at the initial meeting with approximately 67.89% of shares represented.
• Leading independent proxy advisory firms, ISS and Glass Lewis, recommend that stockholders support Proposal No. 2, which could influence undecided votes.
• Management has engaged in constructive conversations with larger stockholders, with many indicating an intention to vote in favor of Proposal No. 2.
• The company is actively soliciting additional votes to ensure the passage of a proposal deemed critical for its Nasdaq listing.

Negatives

• The initial annual meeting was adjourned due to insufficient votes to approve Proposal No. 2, indicating a lack of immediate shareholder consensus or support for a key strategic measure.
• The necessity of a reverse stock split often signals a low stock price, which can be a concern for investors.
• The company faces ongoing risks including continuing operating losses, uncertainty of market acceptance, reliance on third-party manufacturers, accumulated deficit, and future capital needs.

Risks

• Continuing operating losses.
• Uncertainty of market acceptance for the company's products.
• Reliance on third-party manufacturers.
• Accumulated deficit.
• Future capital needs and uncertainty of capital funding.
• Dependence on a limited product line and distribution channels.
• Competition within the biotechnology and vaccine industry.
• Limited marketing and manufacturing experience.

Future Outlook

Vaxart's Board of Directors continues to believe that the proposed reverse stock split (Proposal No. 2) is advisable and in the best interests of stockholders, primarily to ensure the company's continued Nasdaq listing. Management anticipates that successful passage of this proposal will allow the company to focus on its 'exciting upcoming milestones' related to its oral vaccine development programs.

Management Comments

• "In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal," said Steven Lo, Chief Executive Officer of Vaxart.
• "I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones."

Industry Context

Vaxart operates as a clinical-stage biotechnology company specializing in oral recombinant vaccines, a niche area within the pharmaceutical industry that offers potential advantages in administration and storage. The need for a reverse stock split to maintain Nasdaq listing is a common challenge for smaller biotech companies, particularly those in clinical stages, as their stock prices can fluctuate significantly and often trade at lower valuations until key clinical milestones or commercialization. Maintaining listing is crucial for access to capital markets and investor visibility, which are vital for funding ongoing research and development in this capital-intensive industry.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Directly impacted by the voting process for the reverse stock split, which could affect the number of shares they hold and the per-share price, potentially influencing Nasdaq listing status and future investment opportunities.
• **Employees:** The company's ability to maintain Nasdaq listing and secure future funding (potentially facilitated by the reverse split) can impact long-term stability and growth prospects.
• **Nasdaq:** The outcome of Proposal No. 2 directly relates to Vaxart's compliance with Nasdaq listing requirements.

Next Steps

• The reconvened Annual Meeting will be held virtually on Friday, June 13, 2025, at 8:30 a.m. Pacific Time.
• Vaxart will continue to solicit votes from its stockholders for all proposals until the June 12, 2025, 11:59 p.m. ET deadline.
• Stockholders who have not yet voted are encouraged to do so, and those who voted against Proposal No. 2 are reminded they can change their vote.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, Annual Meeting, Reverse Stock Split, Corporate Governance, Nasdaq Listing, Biotechnology, Oral Vaccines, Proxy Solicitation, SEC Filing